Yes, diphenhydramine can potentially cause false positives on certain drug tests, particularly for substances like PCP, methadone, or tricyclic antidepressants.
Many people use diphenhydramine for common issues like allergies or sleep, often without a second thought. Understanding its presence in your system, especially when facing a drug test, is a practical concern for many.
What is Diphenhydramine?
Diphenhydramine is an antihistamine primarily used to relieve symptoms of allergies, such as sneezing, runny nose, and itching. It also has sedative properties, making it a common ingredient in over-the-counter sleep aids. This compound works by blocking histamine H1 receptors in the body, which helps to reduce allergic reactions and induce drowsiness. It is available in various forms, including tablets, capsules, liquids, and topical creams.
Common brand names containing diphenhydramine include Benadryl, ZzzQuil, and Unisom SleepGels. It is widely accessible without a prescription, leading to its frequent use by a broad population.
How Drug Tests Work
Drug tests primarily aim to detect the presence of illicit substances or prescription medications that are misused. The initial screening method for most drug tests is an immunoassay, which is a quick and cost-effective way to identify general classes of drugs. These tests use antibodies that bind to specific drug molecules or their metabolites.
Immunoassays are designed to be highly sensitive, meaning they can detect very low concentrations of target substances. However, this sensitivity can sometimes lead to cross-reactivity, where the antibodies mistakenly bind to compounds structurally similar to the target drug. When an immunoassay yields a positive result, it is considered a presumptive positive. A more precise test, Gas Chromatography-Mass Spectrometry (GC-MS), is then used to confirm the presence and identity of the substance. GC-MS separates and identifies individual compounds based on their unique chemical signatures, eliminating most false positives.
The False Positive Phenomenon
The primary concern with diphenhydramine and drug tests centers on its potential to cause false positive results. This phenomenon is a known limitation of initial immunoassay screenings. It does not mean diphenhydramine is an illicit drug, but rather that its chemical structure can mimic other substances.
Immunoassay Cross-Reactivity
Immunoassays operate on a “lock and key” principle, where specific antibodies (the “locks”) are designed to fit certain drug molecules (the “keys”). Diphenhydramine’s molecular structure possesses similarities to other compounds, particularly those in the phencyclidine (PCP) and tricyclic antidepressant (TCA) classes. When diphenhydramine is present in a urine sample, its molecules can sometimes fit imperfectly into the antibody “locks” intended for PCP or TCAs, triggering a positive signal. This cross-reactivity is not consistent across all immunoassay brands or batches, but it is a well-documented occurrence.
Specific Substances Affected
The most commonly reported false positives due to diphenhydramine are for:
- Phencyclidine (PCP): Diphenhydramine shares structural features that can lead to cross-reactivity with PCP assays.
- Methadone: Some studies and case reports indicate diphenhydramine can interfere with methadone immunoassays.
- Tricyclic Antidepressants (TCAs): Diphenhydramine’s anticholinergic properties and chemical structure can cause false positives for TCAs.
It is important to remember that these are initial screening results. A positive immunoassay for these substances after diphenhydramine use necessitates confirmatory testing.
| Product Category | Common Brand Names | Primary Use |
|---|---|---|
| Antihistamines | Benadryl Allergy, Wal-Dryl | Allergy relief |
| Sleep Aids | ZzzQuil Nighttime Sleep-Aid, Unisom SleepGels | Temporary sleep aid |
| Cold & Flu Remedies | Tylenol PM, Advil PM | Pain relief + sleep aid |
Confirming a False Positive
If an initial immunoassay yields a presumptive positive result, the next step is typically a confirmatory test using Gas Chromatography-Mass Spectrometry (GC-MS) or Liquid Chromatography-Mass Spectrometry (LC-MS). These advanced analytical techniques are highly specific and accurate. They separate the sample into its individual chemical components and then identify each component based on its unique mass-to-charge ratio.
When a sample containing diphenhydramine causes a false positive on an immunoassay for PCP, for example, a GC-MS test will accurately identify diphenhydramine and its metabolites, while finding no actual PCP. This process effectively differentiates between the legitimate medication and the illicit substance, thereby clearing the individual. This is why a presumptive positive result from an initial screen does not automatically mean a person has used an illicit drug.
The Substance Abuse and Mental Health Services Administration (SAMHSA) provides guidelines for workplace drug testing, emphasizing the importance of confirmatory testing for any initial positive screen. This two-step process is standard practice to ensure accuracy and fairness.
Factors Influencing Detection
Several factors can influence how long diphenhydramine remains detectable in a person’s system and its likelihood of causing a false positive. These factors are highly individual and can vary considerably.
- Dosage: Higher doses of diphenhydramine result in higher concentrations in the body, which can increase the chances of detection and potential cross-reactivity.
- Metabolism: Individual metabolic rates play a significant role. People with faster metabolisms may clear the drug more quickly than those with slower metabolisms.
- Frequency of Use: Chronic or regular use can lead to accumulation in the body, extending the detection window compared to a single dose.
- Hydration Level: Diluted urine samples due to high fluid intake might lower drug metabolite concentrations, while concentrated samples could increase them.
- Kidney and Liver Function: These organs are responsible for metabolizing and eliminating drugs. Impaired kidney or liver function can prolong the time diphenhydramine stays in the system.
- Age and Body Mass: Older individuals and those with higher body fat percentages may metabolize and excrete drugs differently.
| Test Type | Detection Window |
|---|---|
| Urine Test | 1-4 days (most common) |
| Blood Test | Up to 12-24 hours |
| Saliva Test | 1-2 days |
| Hair Follicle Test | Up to 90 days (less common for DPH) |
Types of Drug Tests and DPH
Different types of drug tests have varying detection windows for diphenhydramine and its metabolites. Understanding these differences can help clarify expectations.
- Urine Tests: These are the most common type of drug test. Diphenhydramine and its metabolites are typically detectable in urine for 1 to 4 days after the last dose, depending on the factors mentioned above.
- Blood Tests: Blood tests detect the presence of the drug itself in the bloodstream. Diphenhydramine has a relatively short half-life, so it is usually detectable in blood for up to 12-24 hours after ingestion.
- Saliva Tests: Oral fluid or saliva tests can detect diphenhydramine for approximately 1 to 2 days after use. These tests are less invasive and gaining popularity.
- Hair Follicle Tests: Hair tests have the longest detection window, potentially identifying drug use for up to 90 days. While diphenhydramine can be detected in hair, these tests are less frequently used specifically for antihistamines. The concentration in hair might be lower and less consistent than for other substances.
The sensitivity of each test also plays a role. While diphenhydramine can be detected, the primary concern remains its potential to cause false positives on initial immunoassay screens for other substances, regardless of the test matrix.
When to Disclose Medication Use
Transparency about medication use is a practical step when facing a drug test. If you have recently taken diphenhydramine, or any other over-the-counter or prescription medication, it is advisable to disclose this information to the testing administrator or medical review officer (MRO) before or during the testing process. This proactive disclosure can streamline the review process if a presumptive positive result occurs.
The MRO is a licensed physician responsible for reviewing and interpreting drug test results. Their role includes investigating legitimate medical explanations for positive results. Providing documentation, such as a prescription or even just stating your recent use of an over-the-counter product like Benadryl, allows the MRO to consider this information when evaluating the initial screen. This step helps ensure that any false positive due to diphenhydramine is correctly identified and not misinterpreted as illicit drug use. The U.S. Food and Drug Administration (FDA) regulates medications, and their approved uses are part of an MRO’s consideration.
Distinguishing DPH from Illicit Drugs
The key to distinguishing diphenhydramine from illicit drugs lies in the detailed analysis provided by confirmatory tests. While diphenhydramine might trigger an initial immunoassay for substances like PCP, the subsequent GC-MS or LC-MS test provides a definitive identification.
These advanced tests do not just confirm a “positive” or “negative.” They identify the exact chemical structure of the compounds present in the sample. Diphenhydramine has a unique molecular fingerprint, distinct from PCP, methadone, or tricyclic antidepressants. Additionally, these tests can identify specific metabolites. Diphenhydramine is metabolized into compounds like nor-diphenhydramine. The presence of these specific metabolites, and the absence of the actual illicit drug or its metabolites, confirms that the initial positive was a false positive caused by diphenhydramine.
This scientific precision ensures that individuals using legitimate medications are not wrongly accused of illicit drug use, reinforcing the importance of the two-step testing protocol.
References & Sources
- Substance Abuse and Mental Health Services Administration. “SAMHSA.gov” Provides national guidelines and resources for substance abuse prevention and treatment, including drug testing protocols.
- U.S. Food and Drug Administration. “FDA.gov” The federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices.
Mo Maruf
I created WellFizz to bridge the gap between vague wellness advice and actionable solutions. My mission is simple: to decode the research and give you practical tools you can actually use.
Beyond the data, I am a passionate traveler. I believe that stepping away from the screen to explore new environments is essential for mental clarity and physical vitality.